PHARMATECH

Have any questions? Just call us at 720-917-8400

October 28, 2014

Pharmatech Precision Medicine Research System (AccessPPM) Takes Aim at Lung Cancer

Denver, Colorado (October 28, 2014) – Pharmatech seeking biomarker targeting lung cancer studies.

Following the successful launch of AccessPPM, Pharmatech has begun its series of clinical trials in a portfolio of studies planned to treat the different molecular drivers of lung cancer.  This approach, which will also be applied for other types of cancer, is designed to identify all of a patient’s active biomarkers up front, then provide immediate access to research based treatment options matching the patient’s unique biomarker and clinical profiles.

Advances in the molecular biology of cancer are guiding the development of precision medicines targeted to the specific mutations that drive cancer progression. A major challenge to clinical trials of these drugs is that most cancer patients do not receive comprehensive testing to identify all of the mutations (or biomarkers) that are potentially treatable.  Pharmatech has launched a commercial solution, AccessPPM, combining next generation sequencing of more than 500 cancer biomarkers with clinical and treatment history data to help match patients with appropriate clinical trials through their treating oncologist.  Pharmatech is currently working with several large pharma companies to develop a dense pipeline of clinical trials for patients with lung cancer.  The first trials are now enrolling, and the company is seeking to expand collaborations with trial sponsors in 2015.

AccessPPM is designed to deliver research based treatment options covering every treatable biomarker, every subtype of lung cancer, at every treatment stage.  “We want to expand lung cancer patients’ treatment options to include the newest precision medicines,” said Dr. Matthew Wiener, COO.  “AccessPPM enables us to quickly find out which mutations are involved and to deliver the right clinical trial to the oncologist to meet the individual patient’s treatment needs.”  Unlike other molecular profiling based research solutions in the marketplace, AccessPPM is available to all trial sponsors, all investigators and their cancer patients.

Pharmatech CEO, Rob Bohacs commented, “We are thrilled to be integrating our patient centered clinical trial systems with world class molecular diagnostics to deliver research based treatments where and when they are needed most.  This disruptive combination of up-front molecular diagnosis, combined with case matched trial opportunities addresses the major challenge to the clinical development of precision cancer medicines today.”  As the lung cancer research program develops, Pharmatech will launch similar initiatives in other cancer indications where precision medicines are being developed.

 

About Pharmatech, Inc.

Pharmatech, Inc. is an oncology Contract Research Organization (CRO) that specializes in creating efficiencies in the clinical trial process. Through an organized network of cancer clinics, the company focuses on advancing the development of products for a broad range of pharmaceutical and biotechnology companies, and on promoting the inclusion of clinical trials in the spectrum of patient treatment options.

For more information about Pharmatech, please visit: http://www.pharmatech.com or contact us at pr@pharmatech.com

September 30, 2014

Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed

DENVER, Sept. 30, 2014 — According to their CEO, Rob Bohacs – “the world of cancer clinical trials is going through a complete transformation with highly targeted biomarker clinical trials and the work of the current clinical trial management process isn’t configured to accommodate these types of ‘next generation’ clinical trials, which will ultimately drive the prescription cancer drugs of tomorrow.”

The company has been recognized by the National Cancer Institute as an innovator by co-funding its development of AccessPPM and expansion of its Just-In-Time enrollment programs. Mr. Bohacs further stated, “Pharmaceutical companies are feeling the pressure of the challenges associated with highly-targeted drugs and the magnificent cost associated with the old-generation management of these types of clinical trials. We can reduce the time of managing trials by half if we just focus on a more efficient process, ultimately significantly improving the experience for patients and researchers.”

While Pharmatech has been around for nearly 20 years as a service provider to pharmaceutical companies, in the last 2 years the company has completely reinvented itself into a full-fledged genomics and technology company. The company integrated patient medical records with the genetic information from a patient’s tumor to identify the right clinical trial for the patient. It has attracted the attention of the majority of the global pharmaceutical companies as well as the leading research sites from across the US.

ABOUT PHARMATECH
Pharmatech, headquartered in Denver, Colorado, is a Site Management Organization (SMO) and Contract Research Organization (CRO) with a focus on oncology clinical research. Through an organized network of cancer clinics, the Company focuses on advancing the development of products for a broad range of pharmaceutical and biotechnology companies, and on promoting cancer patient care through the inclusion of clinical trials in a spectrum of patient treatment options.

For more information about Pharmatech, please visit: http://www.pharmatech.com or contact us at pr@pharmatech.com

August 5, 2014

Paradigm Initiates Genomic Profiling for Pharmatech’s AccessPPM Cancer Registry Program

ANN ARBOR, Mich. and DENVER, Aug. 5, 2014 –

Paradigm has announced today they have initiated genomic testing for Pharmatech’s AccessPPM Cancer Registry.

Pharmatech’s AccessPPM is a cancer registry designed to collect EMR data and genomic information to help best match cancer patients with targeted clinical trials. The AccessPPM program and associated protocol currently includes 55 sites and is quickly poised to expand to Pharmatech’s entire research network of 345 cancer centers.

“We are truly pleased to begin providing our genomic profiling services for the patients served by AccessPPM,” noted Dr. Robert Penny, CEO of Paradigm. “Our ability to provide clinical grade sequencing through our PCDx test to physician clients in 4-5 business days ensures that continuity of care is maintained and that patients are quickly and efficiently matched to the appropriate therapies and clinical trials. “We anticipate that Pharmatech’s network of sites and cancer centers will be of strategic value to the long-term growth and expansion.”

Rob Bohacs, CEO of Pharmatech, noted, “This is a great milestone as we begin ramping the AccessPPM program. We believe AccessPPM will change the way today’s oncology patient accesses clinical trials and will help pharmaceutical companies identify patients that are truly interested in research.” “Our relationship with Paradigm is a logical and natural fit for this program.”

ABOUT PARADIGM
Paradigm is a non-profit molecular information corporation established to bring cutting-edge diagnostics to cancer patients and clinical trials by providing information about the genomic makeup of the patient’s cancer and potential therapies based on the specific characterization of the patient’s tumor that can impact the patient’s course of treatment. Paradigm’s Next-Generation Sequencing based diagnostic test PCDx provides oncologists and patients with more precise information about the specific cancer pathways in the patient and associations between the pathways and the specific drugs available that can affect the cancer to allow for more effective decision-making. The test is driven by supporting data and literature and provides more choices for patient care than currently available on the market. For more information visitwww.paradigmdx.org.

ABOUT PHARMATECH
Pharmatech, headquartered in Denver, Colorado, is a Site Management Organization (SMO) and Contract Research Organization (CRO) with a focus on oncology clinical research. Through an organized network of cancer clinics, the Company focuses on advancing the development of products for a broad range of pharmaceutical and biotechnology companies, and on promoting cancer patient care through the inclusion of clinical trials in a spectrum of patient treatment options.

Contact: Clare Still, cstill@paradigmdx.org, 734-936-9160, or David Mallery,Dmallery@paradigmdx.org

July 11, 2014

Pharmatech Presents at AACI Annual Clinical Research Initiative Meeting

Denver, Colo. – July 11, 2014

The Association of American Cancer Institutes (AACI) held their 6th annual Clinical Research Initiative (CRI) meeting this week in Chicago and requested that Pharmatech attend as a presenter.

The meeting focused on improving clinical trials management at cancer centers and focused, this year, on “Precision Oncology.” A large shift in the clinical trials industry is shining the spotlight on research ready sites and their ability to identify patients with unique tumor profiles. While these trials can be theory altering for the cancer indication, they are also extremely difficult to complete, due to the extremely small numbers of patients that fit these requirements.

Pharmatech presented on this topic and specifically “Exploring the New Wave of Clinical Trials.” Its chief scientific officer and founder, Dr. Matthew Weiner, discussed how Pharmatech has tackled this momentous challenge of focusing exclusively on the individual patients. Specifically through their AccessPPM program, Pharmatech has addressed this issue head-on and succeeded in enrolling patients into their biomarker identifying database.

“As the landscape of the clinical trials industry changes the challenges faced by clinical research companies are becoming more demanding. Pharmatech is one of the few companies that has addressed these challenges with a dynamic and innovative approach. We were glad to have had the opportunity to share this approach with AACI and its attendees,” said Rob Bohacs, CEO of Pharmatech.


About Pharmatech, Inc.

Pharmatech, headquartered in Denver, Colorado, is a Site Management Organization (SMO) and Contract Research Organization (CRO) exclusively focused on oncology clinical research. Through an organized network of cancer clinics, the Company focuses on advancing the development of products for a broad range of pharmaceutical and biotechnology companies, and on promoting cancer patient care through the inclusion of clinical trials in the spectrum of patient treatment options.

June 17, 2014

EMR data to increase strength of Pharmatech’s current AccessPPM program

Denver, Colo. – June 17, 2014

Pharmatech has officially entered the “big data” arena in the world of clinical oncology, through its AccessPPM molecular diagnostic protocol and its partnership with Paradigm.

Pharmatech and Paradigm are joining clinical EMR data with comprehensive next generation sequencing to provide new insight into patient treatment and outcomes from a molecular understanding. Earlier in the year, Pharmatech launched AccessPPM, a registry designed to collect EMR data and an extensive biomarker profile to help match patients with the next generation of clinical trials – of highly targeted anti-cancer medicines which may provide a significantly brighter future for cancer patients. The AccessPPM protocol is commencing with 55 sites across the US, then will expand beyond Pharmatech’s entire research network of 345 cancer centers across the US.

Another major benefit of AccessPPM, is the registry of case matched molecular data it collects. This will yield significant value to pharmaceutical companies, to better understand how their drugs interact with and alter tumors within the context of specific biomarkers.

According to Rob Bohacs, CEO, “This could yield significant clues to big pharma to where their drugs are most effective, if they are being used off label, and the level of efficacy they may be realizing in populations that are stratified by biomarkers. In addition, we may see alterations at a genetic level that may not necessary yield clinical efficacy, but may transform the genetic structure of the tumor where a secondary drug then could be more effective.”

Bohacs believes it’s truly a special time in oncology and one of the most powerful tools may be data and computing power.


About Pharmatech, Inc.

Pharmatech, headquartered in Denver, Colorado, is a Site Management Organization (SMO) and Contract Research Organization (CRO) exclusively focused on oncology clinical research. Through an organized network of cancer clinics, the Company focuses on advancing the development of products for a broad range of pharmaceutical and biotechnology companies, and on promoting cancer patient care through the inclusion of clinical trials in the spectrum of patient treatment options.


About Paradigm

Paradigm is a non-profit corporation established to bring cutting-edge diagnostics to cancer patients and clinical trials by providing additional information about the genomic makeup of the patient’s cancer and potential therapies based on the specific characterization of the patient’s tumor that can impact the patient’s course of treatment. Paradigm’s diagnostic test provides oncologists and patients with more precise information about the specific cancer pathways in the patient and associations between the pathways and the specific drugs available that can affect the cancer to allow for more effective decision-making. The test is driven by supporting data and literature and provides more choices for patient care than currently available on the market.

June 2, 2014

Enrollment in Pharmatech’s Revolutionary AccessPPM Program Launches

Denver, Colo. – June 2, 2014

Pharmatech commences enrollment for its AccessPPM program after a two year investment into this game-changing method for matching cancer patients to cancer clinical trials.

Utilizing the Paradigm Cancer Diagnostic (PCDx) molecular profiling and patients’ treatment history, AccessPPM matches patients into the clinical trial that is suited for their disease. Clinical trials of today are targeted at specific cancers, disease staging, as well as genetic mutations – which may be a contributing factor for the cancer in the first place. The challenge is that this information may not be well known to the patient or even their treating oncologist. Therefore, patients in AccessPPM have their tumor biopsy analyzed for over expression of certain biomarkers and are matched with the right study.

Rob Bohacs, CEO of Pharmatech, commented, “We are sincerely pleased to begin the enrollment phase of this program and begin to match patients with clinical trials at a genetic level. The evolution of research today is transforming and research is accelerating, but there is a disconnect between patients’ understanding of their disease and the complexity of clinical trails. Clinical trials are being designed to target mutations at a cellular level and that complexity challenges the ability to match patients to the right study. AccessPPM will change the way patients access clinical trials and will help pharmaceutical companies identify patients that are interested in research.”

The comprehensive molecular testing will be performed by Paradigm at their commercial laboratory at the University of Michigan. The Paradigm PCDx test evaluates over 500 molecular abnormalities and delivers those results in one week, to the treating physician. The test evaluates the known, clinically actionable mutations for solid tumor malignancies, and provides specific associations for potential FDA approved therapies and investigational treatments.


About Pharmatech, Inc.

Pharmatech, headquartered in Denver, Colorado, is a Site Management Organization (SMO) and Contract Research Organization (CRO) with a focus on oncology clinical research. Through an organized network of cancer clinics, the Company focuses on advancing the development of products for a broad range of pharmaceutical and biotechnology companies, and on promoting cancer patient care through the inclusion of clinical trials in a spectrum of patient treatment options.


About Paradigm

Paradigm is a non-profit corporation established to bring cutting-edge diagnostics and biomarker driven clinical trials to benefit cancer patients. Through Next-Gen Sequencing, and other biomarker analysis, Paradigm is able to provide information about the genomic landscape of a patient’s cancer, as well as potential therapies based on the specific characterization of the patient’s tumor; thus, personalizing each patient’s course of treatment. Paradigm’s cancer diagnostic test, PCDx, provides oncologists with more precise information about the specific cancer pathways in the patient and associations between the pathways and the specific drugs available that can affect the cancer to allow for more effective decision-making. The test is driven by supporting data and literature and provides more choices for patient care than currently available on the market. Paradigm, headquartered in Ann Arbor, Michigan with research facilities in downtown Phoenix, Arizona, is a collaboration between the University of Michigan Health System and the International Genomics Consortium.

May 8, 2014

Pharmatech to Attend American Society of Clinical Oncology’s 50th Annual Meeting

Denver, Colo. – May 8, 2014

Between the end of May and the beginning of June, the world of clinical oncology is attentively focused on the advancements of cancer drugs as the American Society of Clinical Oncology (ASCO) meeting commences.

Pharmatech shall attend ASCO’s 50th annual meeting this year and has been an annual participant of ASCO for 14 years. With over 26,000 oncology professionals attending in years past, the venue becomes a great opportunity to centralize meetings with industry professionals. The ASCO event is hosted in Chicago, Illinois and attracts a global audience.

This year, Pharmatech will focus on their newest contribution to clinical research, AccessPPM – a molecular screening program that is the next stage of the company’s evaluation to align cancer patients with complex oncology clinical trials.

With the world of clinical oncology beginning to focus on biomarker-driven clinical trials, or the genetic makeup of a tumor, AccessPPM will become an invaluable asset to clinical program managers to more efficiently manage the enrollment of clinical trials. Please visit Pharmatech at ASCO for additional information about AccessPPM (Booth #12162).

Rob Bohacs, CEO, stated, “We are excited to use ASCO to further introduce our AccessPPM program to sponsors as we officially launched the program in 2014, after years of investment. We are always eager to learn about the continuing evolution on the drug development programs and now we’re able to help support the micro-targeted programs with AccessPPM and electronically match patients to clinical trials at a molecular level – it’s truly remarkable.”


About Pharmatech, Inc.

Pharmatech, headquartered in Denver, Colorado, is a Site Management Organization (SMO) and Contract Research Organization (CRO) with a focus on oncology clinical research. Through an organized network of cancer clinics, the company focuses on advancing the development of products for a broad range of pharmaceutical and biotechnology companies, and promoting the inclusion of clinical trials in the spectrum of patient treatment options.

May 2, 2014

Pharmatech Announces New Executive Director of Data Management

Denver, Colo. – May 2, 2014

Pharmatech appointed Linda Martz to the new position of Executive Director of Data Management.

Martz most recently held the position of Executive Director, Data Management, for TFS, a global CRO. Prior to that, she built the Data Management department for Beardsworth Consulting Group, Inc., a privately-held, oncology-focused CRO based in NJ.

In addition to being an Executive in Data Management services since 2000, she has been in clinical research for over 30 years; as a Study Coordinator and Research Nurse, as a Clinical Site Manager and a Data Management and Project Director in a variety of settings- hospitals, large and small CROs, and sponsor/Pharmaceutical companies. She is a member of the Oncology Nursing Society and Society for Clinical Data Management, and is MedDRA certified. Martz has worked with many EDC systems, and on many complex studies. From her research and medical background, to her practical knowledge of data management, biostatistics, CDISC, CDASH, SAS programming and project delivery, to her expertise in creating client satisfaction, Martz is an important new voice for Pharmatech in 2014.

Rob Bohacs, CEO, stated: “We are very excited to continue to build our executive team of professionals. We are migrating into an exciting new position that is revolutionizing the clinical trial management process that requires the right team of professionals and Linda will be a welcome addition. We are always seeking to recruit key industry professionals to join our exciting team.”


About Pharmatech, Inc.

Pharmatech, headquartered in Denver, Colorado, is a Site Management Organization (SMO) and Contract Research Organization (CRO) with a focus on oncology clinical research. Through an organized network of cancer clinics, the company focuses on advancing the development of products for a broad range of pharmaceutical and biotechnology companies, and promoting the inclusion of clinical trials in the spectrum of patient treatment options.

Contact: Wendy Jones wjones@pharmatech.com 789 Sherman St. Suite 310 Denver, CO 80203 Ph: (720) 917-7465

April 23, 2014

Pharmatech Announces New Controller

Denver, Colo. – April 23, 2014

Pharmatech recently announced that it has hired Pat Mancini as its new controller.

Mancini previously held the position of Director of Finance, North America, for TFS, a global CRO. Over his career at Beardsworth Consulting Group, Inc., he was constantly promoted and held positions of increasing responsibility. From his initial promotion from Operations Analyst, to Finance Manager, he continued his upward climb to Controller, Business Solutions Manager and finally Chief Financial Officer. With his vast knowledge of finance in a clinical research setting, Mancini’s team-focused approach and track record of success is a great asset to Pharmatech, as well as their clients and sites.

Rob Bohacs, CEO, stated: “As Pharmatech continues to improve its executive leaders, Pat Mancini stands out as a rare and welcome addition to our team. Our continuous effort to employ only the highest caliber candidates is what has lead to Pharmatech’s success and Pat’s appointment is no exception.”


About Pharmatech, Inc.

Pharmatech, headquartered in Denver, Colorado, is a Site Management Organization (SMO) and Contract Research Organization (CRO) with a focus on oncology clinical research. Through an organized network of cancer clinics, the company focuses on advancing the development of products for a broad range of pharmaceutical and biotechnology companies, and promoting the inclusion of clinical trials in the spectrum of patient treatment options.

Contact: Wendy Jones wjones@pharmatech.com 789 Sherman St. Suite 310 Denver, CO 80203 Ph: (720) 917-7465

April 14, 2014

Pharmatech Announces a New Senior Director of Business Development

Denver, Colo. – April 14, 2014

Pharmatech hired Chris Fallows to fill the newly created position of Senior Director of Business Development.

Fallows, previously Senior Director, Client Services at Applied Clinical Intelligence, sold Oncology CRO services at Novella and Premier, and most recently sold stand-alone services for DMC, DSMB and Stats, to Pharmaceutical, Biotech, Device, CRO clients. Over the last 5 years, he focused on sales, helping companies like Novella grow from 80 employees to a company of 950. Based in Chicago, IL, he has been a mid-west-based Business Development professional in the pharmaceutical industry for over 15 years. Fallows’ solid sales experience, expertise in creating company growth, along with his personal drive, make him an important addition to Pharmatech’s talent this year.

Rob Bohacs, CEO, stated: “Pharmatech is very enthusiastic about the opportunities and mutual growth that Chris Fallows affords us, as an asset. With Chris’ extensive experience and background he is already a valuable member of Pharmatech.”


About Pharmatech, Inc.

Pharmatech, headquartered in Denver, Colorado, is an oncology focused Contract Research Organization (CRO) and Site Management Organization (SMO). Through an organized network of cancer clinics, the company focuses on accelerating the development of products for a broad range of pharmaceutical and biotechnology companies, and promoting the inclusion of clinical trials in the spectrum of patient treatment options.

Contact: Wendy Jones wjones@pharmatech.com 789 Sherman St. Suite 310 Denver, CO 80203 Ph: (720) 917-7465